Literature DB >> 23599873

More on cholesterol trafficking in the body!

Khawla Al-Musalhi1, Devaki R Nair.   

Abstract

Entities:  

Year:  2013        PMID: 23599873      PMCID: PMC3628207          DOI: 10.5001/omj.2013.23

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


× No keyword cloud information.
  18 in total

Review 1.  Genetic variability in response to infection: malaria and after.

Authors:  D J Weatherall; J B Clegg
Journal:  Genes Immun       Date:  2002-09       Impact factor: 2.676

Review 2.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.

Authors:  G Tibolla; G D Norata; R Artali; F Meneghetti; A L Catapano
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-09-23       Impact factor: 4.222

Review 3.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

4.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Authors:  Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratne; Fannie Huang; Thomas Liu; Satishkumar Mohanavelu; Elaine B Hoffman; Shannon T McDonald; Timothy E Abrahamsen; Scott M Wasserman; Robert Scott; Marc S Sabatine
Journal:  Lancet       Date:  2012-11-06       Impact factor: 79.321

Review 5.  Hepatitis C virus particles and lipoprotein metabolism.

Authors:  Patrice André; Gabriel Perlemuter; Agata Budkowska; Christian Bréchot; Vincent Lotteau
Journal:  Semin Liver Dis       Date:  2005-02       Impact factor: 6.115

6.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Authors:  Kara N Maxwell; Edward A Fisher; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

7.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

Authors:  Jean Davignon; Geneviève Dubuc
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

9.  Genetic variants in PCSK9 affect the cholesterol level in Japanese.

Authors:  Keisuke Shioji; Toshifumi Mannami; Yoshihiro Kokubo; Nozomu Inamoto; Shuichi Takagi; Yoichi Goto; Hiroshi Nonogi; Naoharu Iwai
Journal:  J Hum Genet       Date:  2004-01-15       Impact factor: 3.172

10.  Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

Authors:  Holly E Careskey; R Aleks Davis; William E Alborn; Jason S Troutt; Guoqing Cao; Robert J Konrad
Journal:  J Lipid Res       Date:  2007-11-21       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.